Immunovaccine Inc.

Immunovaccine Inc.

Immunovaccine Inc.

Immunovaccine Inc. (TSX-V: IMV) develops vaccines, using its patented delivery platform – DepoVax™ – for therapeutic cancer and infectious diseases.
Founded
2000
Raised
$17M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$5,750,000
Venture capital - 2018
Fonds de solidarité FTQ
$11,200,000
Post-IPO equity - 2014
Team Size
10+
Employees
Location
Headquarters
$5,750,000 Venture capital
PE HUB

Fonds de solidarité FTQ puts $5.75 mln to work in Immunovaccine

Health Funding